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In this month’s edition of the Journal of Thoracic Oncology, Farjah et al.1 present a “predic-
tion model for pathologic N2 disease in lung cancer patients with negative mediastinum by 
PET/CT,” where PET/CT refers to positron emission tomography/computed tomography. The 
background for their investigation is the fact that a clear algorithm currently exists on how to 
proceed with positive PET/CT findings on initial staging investigations in suspected locally 
advanced non–small-cell lung cancer (NSCLC).2 However, more loose guidelines exist in the 
case of both CT- and PET/CT-negative evaluation of the mediastinal nodes, and institutional 
policies for this situation differ considerably. They present here a very large, single-institu-
tional cohort study on 938 patients from Memorial Sloan Kettering Cancer Center in New 
York, reporting on a rather homogeneous group of patients with T1 and T2 primary lesions 
on CT scans and PET-CT findings of N0 or N1.1 Patients were planned for curative resection, 
but invasive mediastinal staging was implemented only selectively based on the individual 
decision by the handling surgeon in patients where clinical factors were suggestive of high 
risk of occult N2 disease in the mediastinum. Of all 938 patients overall 9.9% were diagnosed 
as having N2 nodes infiltrated by tumor, but only in nine these were detected with invasive 
mediastinal staging whereas in 84 patients N2 disease was only confirmed pathologically 
based on the findings in the resected specimen and mediastinal nodes from mediastinal lymph 
node sampling/dissection at the time of surgery. In nine patients the preoperative invasive 
staging procedure showed finally to be a false-negative result, giving a sensitivity of 50% for 
this procedure. Farjah et al. point out that in most cases the indication to perform an invasive 
mediastinal staging is based on an individual, rather subjective, decision by the responsible 
surgeon. This is typically relying on some clinical characteristics such as central location of 
the primary and hilar lymph node involvement, which are more or less indicative of a high 
risk of mediastinal disease. Their aim was clearly to develop more objective and reproducible 
criteria for predicting the positivity of lymph nodes in the mediastinum, based on some risk 
factors that are available before surgery and that have already been described in the literature 
and could be evaluated here in all analyzed patients of this homogeneous patient cohort.3
Six factors were finally included to this investigation: tumor location—central versus 
peripheral—and tumor size based on initial CT scans, extent of nodal disease by CT, maxi-
mum standardized uptake value (SUV
max
) of the primary tumor in PET, N1-disease by PET 
and tumor histopathology. These six parameters had been previously described to be signifi-
cantly associated with the risk of N2 involvement to be revealed at the time of surgery.3 The 
authors of the discussed manuscript used a complex logistical regression model and also 
implemented a development set (about two third of the population) and a validation set for the 
model (about one third of the population).
Although initial univariate analyses showed significant association between increased 
tumor size, nodal status by CT, SUV
max
 of the primary tumor, N1 by PET on one side and N2 
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status proven at the time of surgery on the other, only the latter of 
the factors turned out to be significant in the following multivari-
ate predictive model. So the final predictive model was based on 
“PET findings of N1 disease” as the only remaining important 
parameter in the model. Evaluation of this predictive model by 
C statistic and goodness-of-fit showed it to be performing rea-
sonably well. The authors conclude from their findings that this 
result can in the future be used to guide further research on the 
development of objective prediction models for N2 disease in 
the mediastinum. Again, in comparison to the rather subjective 
decision making by individual thoracic surgeons of a single or 
even several different institutions, this parameter-guided most 
objective approach offers several advantages. Besides allowing 
thoracic surgeons to move away from subjective decision mak-
ing, such data sets could also help to rationally reduce patient 
risks as well as costs related to unnecessary invasive staging 
methods in early or locally advanced NSCLC.1
We will not cover the issues related to the development 
of the new technologies such as endobronchial ultrasound 
and endoesophageal ultrasound for the invasive staging of the 
mediastinum here, although they have important implications 
on the whole staging algorithm as it is currently developing.3 
This is of major importance, especially in patients who are 
candidates for nonsurgical procedures, such as stereotactic 
body radiotherapy, and in these situations a false-negative rate 
of predicting mediastinal involvement of 50% is clearly not 
acceptable.
Can predictive models help to completely substitute 
experienced clinical decision making in locally advanced 
NSCLC? The answer is probably both—yes and no—and no 
final statement is currently possible on this controversy.
One of the main issues with stage III disease in NSCLC 
is the existing heterogeneity of patients not only based on stag-
ing including mediastinal involvement, but also on the comor-
bidity profiles of the patients and even more with the available 
permutations of multimodality treatment approaches that could 
potentially be performed in the setting of the individual patient.4 
Examples for these important influences may be seen in the lung 
function in the individual patient, which determine any aggres-
sive local approach whether it is surgery on the one hand or defin-
itive chemoradiation on the other. Another good example is the 
problem that adjuvant chemotherapy after extended resections 
(e.g., pneumonectomies) may be rather risky and alternatively, 
in these patients, induction chemotherapy followed by definitive 
surgery may be much easier and less risky to the patients regard-
ing infectious complications during chemotherapy. But these situ-
ations are only relevant typically for small subsets of patients and, 
unfortunately for these small subsets, little evidence from larger 
patient groups or trials is currently available in the literature.
Can we change this dilemma? Only if more stage III 
patients would be treated in prospective randomized trials in 
the future! Deriving data from large retrospective data sets 
from single institutions as the one presented in this article is 
an important contribution to the “current body of evidence” 
in this setting and the authors can only be congratulated for 
including nearly 1000 patients from 2004 to 2009 in this 
detailed analyses and for having all the necessary parameters 
documented in the patient cohort.
However, the next step for us all should be to routinely 
treat all curatively intended patients in prospective clinical tri-
als (preferably also controlled ones). We are realistic—this is 
more of wishful thinking—the current reality bites very, very 
hard. . . Only a few prospective randomized clinical trials in 
stage III have been performed within the recent years! We will 
need a joint effort by large national or even international study 
groups to speed up clinical research for these curative situa-
tions with highest needs for clinical evidence. Recent develop-
ments with the large International Association for the Study of 
Lung Cancer staging project and with the European Thoracic 
Oncology Platform projects in Europe are highlight platforms 
for this important diagnostic as well as therapeutic workup 
of large enough patient groups to help us further develop the 
diagnostic and therapeutic options for the individual NSCLC 
patient!5,6
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